Post Profile






Roche lymphoma drug drives high remission rate, longer survival: study

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.
read more

share

Related Posts


'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Health : Reuters: Health

(Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, ear...

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remaine...

Novartis CAR-T therapy leads to durable response in lymphoma study

Health : Reuters: Health

(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to update...

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Health : Newswise Medical News

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment wit...

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

Health : Reuters: Health

(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results...

Comments


Copyright © 2016 Regator, LLC